Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary B Gordon

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Molecular Cancer Therapeutics|July 15, 2004
A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathwayYuesheng Zhang, Gary B Gordon
Analytical Chemistry|December 2, 2004
Hybridization enhancement using microfluidic planetary centrifugal mixingMagdalena A Bynum, Gary B Gordon
Chemotherapy|November 14, 2012
A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patientsTian Ma, Alexander D Fuld, James R Rigas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 4, 2011
A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapyRajesh V Lalla, Gary B Gordon, Mark Schubert, et al.
Anticancer Research|July 2, 2014
Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and managementHao Xiong, Rajendra S Pradhan, Adel Nada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinomaScot Ebbinghaus, Maha Hussain, Nizar Tannir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcomaLaurence H Baker, Eric K Rowinsky, David Mendelson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
A phase II study of ABT-751 in patients with advanced non-small cell lung cancerAnn M Mauer, Ezra E W Cohen, Patrick C Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 studyKenneth R Hande, Anne Hagey, Jordan Berlin, et al.
Anti-Cancer Drugs|April 29, 2009
ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculatureYanping Luo, Vincent P Hradil, David J Frost, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Molecular Cancer Therapeutics|July 15, 2004
A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathwayYuesheng Zhang, Gary B Gordon
Analytical Chemistry|December 2, 2004
Hybridization enhancement using microfluidic planetary centrifugal mixingMagdalena A Bynum, Gary B Gordon
Chemotherapy|November 14, 2012
A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patientsTian Ma, Alexander D Fuld, James R Rigas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 4, 2011
A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapyRajesh V Lalla, Gary B Gordon, Mark Schubert, et al.
Anticancer Research|July 2, 2014
Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and managementHao Xiong, Rajendra S Pradhan, Adel Nada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinomaScot Ebbinghaus, Maha Hussain, Nizar Tannir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcomaLaurence H Baker, Eric K Rowinsky, David Mendelson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
A phase II study of ABT-751 in patients with advanced non-small cell lung cancerAnn M Mauer, Ezra E W Cohen, Patrick C Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 studyKenneth R Hande, Anne Hagey, Jordan Berlin, et al.
Anti-Cancer Drugs|April 29, 2009
ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculatureYanping Luo, Vincent P Hradil, David J Frost, et al.
Pageof 2